

Haematologica
HAEMATOL/2018/195453
Version 3

Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients with intensive chemotherapy

Anne-Sophie Brunel, Agnieszka Wójtowicz, Frédéric Lamoth, Olivier Spertini, Dionysios Neofytos, Thierry Calandra, Oscar Marchetti, and Pierre-Yves Bochud

Disclosures: Acknowledgements The authors would like to thank the patients who participated to the study. They acknowledge the contribution of study nurses (Aurélie Guillet, Corine Guyaz, Monika Ochsner, Annie Savoie, Isabel Cobos) and physicians (Estelle Moulin) for collection of clinical data and blood samples as well as of the laboratory team (Emilie Collinet, Anne-Laure Chanson, Didier Le-Roy, Bertrand Betrisey, Thierry Roger, Stéphanie Bibert) for blood samples processing and genotyping. They thank collaborators from the clinical research center (Ali Maghraoui, Fady Fares, Isabelle Guilleret, Marc Froissart, Vassili Soumas) and the biobanking platform (Pierre Chodanowsky, Elodie Ristorcelli, Didier Foretay and Nathalie Jacquemont). Financial support PYB was supported by the Swiss National Foundation (grant number 324730-165954 and 32003B-127613), the Leenaards Foundation and the Santos-Suarez Foundation. ASB was supported by Carigest SA and Promex Stiftung für die Forschung. OM was supported by the Foundation for the Advancement in Medical Microbiology and Infectious Diseases (FAMMID), the Fungal Infection Network of Switzerland (FUNGINOS), and the Leenaards Foundation. **Disclosure of Conflicts of Interest** - ASB reports grants from Promex Stiftung für die Forschung (by Carigest SA), during the conduct of the study; other from Gilead, outside the submitted work; - PYB reports personal fees from Pfizer, Basilea, personal fees from MSD, outside the submitted work; - TC reports other from Astellas, other from Cubist (Subsequently acquired by MSD), other from Basilea, other from Cidara, other from Debiopharm, other from MSD, other from Abbott, other from Biocartis, during the conduct of the study; other from Sobi, other from Novartis, outside the submitted work; - AW, FL, OS, DN, OM : They have nothing to disclose.

Contributions: ASB, AW, OM and PYB established the study design (ASB, OM and PYB: case report form and clinical database; OM and PYB: biobank; ASB, AW, PYB: genetic association study), with contributions from FL and OS; ASB, AW and PYB performed the study (ASB: clinical data collection; ASB and PYB: data management; AW and PYB: genotyping; ASB, AW and PYB: statistical analyses), with contributions from OM, FL and TC; ASB, AW and PYB wrote the manuscript, with contributions from DN as well as the other co-authors.